Top

Published in:

Open Access 01-12-2021 | Multiple Sclerosis | Research article

The possible role of Interleukin-6 as a regulator of insulin sensitivity in patients with neuromyelitis optica spectrum disorder

Authors: Zhila Maghbooli, Abdorreza Naser Moghadasi, Nasim Rezaeimanesh, Abolfazl Omidifar, Tarlan Varzandi, Mohammad Ali Sahraian

Published in: BMC Neurology | Issue 1/2021

Abstract

Background

Neuromyelitis optica spectrum disorder (NMOSD) is associated with inflammatory mediators that may also trigger downstream signaling pathways leading to reduce insulin sensitivity.

Methods

We aimed to determine the risk association of hyperinsulinemia in NMOSD patients with seropositive AQP4-IgG and the serum levels of interleukin (IL)-6 and IL-17A compared with the control group.

Serum levels of metabolic (Insulin, Fasting Blood Sugar (FBS), lipid profile) and inflammatory (IL-6 and IL-17) markers were assessed in 56 NMOSD patients and 100 controls.

Results

Hyperinsulinemia was more prevalent in NMOSD patients independent of age, sex and body mass index (BMI) (48.2% vs. 26%, p = 0.005) compared to control group. After adjusting age, sex and BMI, there was significant association between lower insulin sensitivity (IS) and NMOSD risk (95% CI: Beta = 0.73, 0.62 to 0.86, p = 0.0001).

Circulating levels of IL-6 and IL-17 were higher in NMOSD patients, and only IL-6 had an effect modifier for the association between lower insulin sensitivity and NMOSD risk.

Conclusions

Our data suggests that inflammatory pathogenesis of NMOSD leads to hyperinsulinemia and increases the risk of insulin resistance.

Available only for authorised users

Wingerchuk DM, Hogancamp WF, O'Brien PC, Weinshenker BG. The clinical course of neuromyelitis optica (Devic's syndrome). Neurology. 1999;53(5):1107–14. https://doi.org/10.1212/WNL.53.5.1107.CrossRefPubMed

Hor JY, Asgari N, Nakashima I, Broadley SA, Leite MI, Kissani N, et al. Epidemiology of Neuromyelitis Optica Spectrum Disorder and Its Prevalence and Incidence Worldwide. Front Neurol. 2020;11(501):1–13. https://doi.org/10.3389/fneur.2020.00501.

Eskandarieh S, Nedjat S, Azimi AR, Moghadasi AN, Sahraian MA. Neuromyelitis optica spectrum disorders in Iran. Multiple Sclerosis Relat Disord. 2017;18:209–12. https://doi.org/10.1016/j.msard.2017.10.007.CrossRef

Etemadifar M, Dashti M, Vosoughi R, Abtahi SH, Ramagopalan SV, Nasr Z. An epidemiological study of neuromyelitis optica in Isfahan. Multiple sclerosis (Houndmills, Basingstoke, England). 2014;20(14):1920–2.CrossRef

Kashipazha D, Mohammadianinejad SE, Majdinasab N, Azizi M, Jafari M. A descriptive study of prevalence, clinical features and other findings of neuromyelitis optica and neuromyelitis optica spectrum disorder in Khuzestan Province, Iran. Irani J Neurol. 2015;14(4):204–10.

Wingerchuk DM, Lennon VA, Lucchinetti CF, Pittock SJ, Weinshenker BG. The spectrum of neuromyelitis optica. Lancet Neurol. 2007;6(9):805–15. https://doi.org/10.1016/S1474-4422(07)70216-8.CrossRefPubMed

Lennon VA, Wingerchuk DM, Kryzer TJ, Pittock SJ, Lucchinetti CF, Fujihara K, et al. A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis. Lancet. 2004;364(9451):2106–12.CrossRef

Levin MH, Bennett JL, Verkman AS. Optic neuritis in neuromyelitis optica. Prog Retin Eye Res. 2013;36:159–71. https://doi.org/10.1016/j.preteyeres.2013.03.001.CrossRefPubMedPubMedCentral

Gold SM, Willing A, Leypoldt F, Paul F, Friese MA. Sex differences in autoimmune disorders of the central nervous system. Semin Immunopathol. 2019;41(2):177–88. https://doi.org/10.1007/s00281-018-0723-8.CrossRefPubMed

10.

Zekeridou A, Lennon VA. Aquaporin-4 autoimmunity. Neurol Neuroimmunol Neuroinflamm. 2015;2(4):e110. https://doi.org/10.1212/NXI.0000000000000110.CrossRefPubMedPubMedCentral

11.

Pittock SJ, Weinshenker BG, Lucchinetti CF, Wingerchuk DM, Corboy JR, Lennon VA. Neuromyelitis optica brain lesions localized at sites of high aquaporin 4 expression. Arch Neurol. 2006;63(7):964–8. https://doi.org/10.1001/archneur.63.7.964.CrossRefPubMed

12.

Weinshenker BG, Wingerchuk DM. Neuromyelitis Spectrum disorders. Mayo Clin Proc. 2017;92(4):663–79. https://doi.org/10.1016/j.mayocp.2016.12.014.CrossRefPubMed

13.

Ito S, Mori M, Makino T, Hayakawa S, Kuwabara S. “Cloud-like enhancement” is a magnetic resonance imaging abnormality specific to neuromyelitis optica. Ann Neurol. 2009;66(3):425–8. https://doi.org/10.1002/ana.21753.CrossRefPubMed

14.

Wang X, Jiao W, Lin M, Lu C, Liu C, Wang Y, et al. Resolution of inflammation in neuromyelitis optica spectrum disorders. Multiple Sclerosis Relat Disord. 2019;27:34–41. https://doi.org/10.1016/j.msard.2018.09.040.CrossRef

15.

Wang KC, Lee C-L, Chen S-Y, Chen J-C, Yang C-W, Chen S-J, et al. Distinct serum cytokine profiles in neuromyelitis optica and multiple sclerosis. J Interf Cytokine Res. 2013;33(2):58–64. https://doi.org/10.1089/jir.2012.0040.CrossRef

16.

Uzawa A, Masahiro M, Kuwabara S. Cytokines and chemokines in neuromyelitis optica: pathogenetic and therapeutic implications. Brain Pathol. 2014;24(1):67–73. https://doi.org/10.1111/bpa.12097.CrossRefPubMed

17.

Hotamisligil GS, Shargill NS, Spiegelman BM. Adipose expression of tumor necrosis factor-alpha: direct role in obesity-linked insulin resistance. Science (New York, NY). 1993;259(5091):87–91.CrossRef

18.

Jager J, Grémeaux T, Cormont M, Le Marchand-Brustel Y, Tanti JF. Interleukin-1beta-induced insulin resistance in adipocytes through down-regulation of insulin receptor substrate-1 expression. Endocrinology. 2007;148(1):241–51. https://doi.org/10.1210/en.2006-0692.CrossRefPubMed

19.

de Luca C, Olefsky JM. Inflammation and insulin resistance. FEBS Lett. 2008;582(1):97–105. https://doi.org/10.1016/j.febslet.2007.11.057.CrossRefPubMed

20.

Castañeda S, Remuzgo-Martínez S, López-Mejías R, Genre F, Calvo-Alén J, Llorente I, et al. Rapid beneficial effect of the IL-6 receptor blockade on insulin resistance and insulin sensitivity in non-diabetic patients with rheumatoid arthritis. Clin Exp Rheumatol. 2019;37(3):465473.

21.

Kuo C-Y, Tsai T-Y, Huang Y-C. Insulin resistance and serum levels of adipokines in patients with systemic lupus erythematosus: a systematic review and meta-analysis. Lupus. 2020;29(9):1078–84. https://doi.org/10.1177/0961203320935185.CrossRefPubMed

22.

Camins A, Lopez JF, Olloquequi J, Ettcheto M, Busquets O, Sanchez López E, et al. The involvement of peripheral and brain insulin resistance in late onset Alzheimer’s dementia. Front Aging Neurosci. 2019;11:236.CrossRef

23.

Oliveira SR, Simão ANC, Kallaur AP, de Almeida ERD, Morimoto HK, Lopes J, et al. Disability in patients with multiple sclerosis: influence of insulin resistance, adiposity, and oxidative stress. Nutrition. 2014;30(3):268–73. https://doi.org/10.1016/j.nut.2013.08.001.CrossRefPubMed

24.

Ruiz-Argüelles A, Méndez-Huerta MA, Lozano CD, Ruiz-Argüelles GJ. Metabolomic profile of insulin resistance in patients with multiple sclerosis is associated to the severity of the disease. Multiple Sclerosis Relat Disord. 2018;25:316–21. https://doi.org/10.1016/j.msard.2018.08.014.CrossRef

25.

Straub RH. Insulin resistance, selfish brain, and selfish immune system: an evolutionarily positively selected program used in chronic inflammatory diseases. Arthritis Res Ther. 2014;16 Suppl 2(Suppl 2):S4.CrossRef

26.

Fernández-Real JM, Ricart W. Insulin resistance and inflammation in an evolutionary perspective: the contribution of cytokine genotype/phenotype to thriftiness. Diabetologia. 1999;42(11):1367–74. https://doi.org/10.1007/s001250051451.CrossRefPubMed

27.

Lozovoy MAB, Simao A, Hohmann M, Simao T, Barbosa D, Morimoto HK, et al. Inflammatory biomarkers and oxidative stress measurements in patients with systemic lupus erythematosus with or without metabolic syndrome. Lupus. 2011;20(13):1356–64. https://doi.org/10.1177/0961203311411348.CrossRefPubMed

28.

Wingerchuk DM, Lennon VA, Pittock SJ, Lucchinetti CF, Weinshenker BG. Revised diagnostic criteria for neuromyelitis optica. Neurology. 2006;66(10):1485–9. https://doi.org/10.1212/01.wnl.0000216139.44259.74.CrossRefPubMed

29.

Balkau B, Charles MA. Comment on the provisional report from the WHO consultation. European Group for the Study of insulin resistance (EGIR). Diabetic Med. 1999;16(5):442–3. https://doi.org/10.1046/j.1464-5491.1999.00059.x.CrossRefPubMed

30.

Lissner L, Bengtsson C, Lapidus L, Kristjansson K, Wedel H. Fasting insulin in relation to subsequent blood pressure changes and hypertension in women. Hypertension (Dallas, Tex : 1979). 1992;20(6):797–801.CrossRef

31.

Katz A, Nambi SS, Mather K, Baron AD, Follmann DA, Sullivan G, et al. Quantitative insulin sensitivity check index: a simple, accurate method for assessing insulin sensitivity in humans. J Clin Endocrinol Metab. 2000;85(7):2402–10. https://doi.org/10.1210/jcem.85.7.6661.CrossRefPubMed

32.

Penesova A, Vlcek M, Imrich R, Vernerova L, Marko A, Meskova M, et al. Hyperinsulinemia in newly diagnosed patients with multiple sclerosis. Metab Brain Dis. 2015;30(4):895–901. https://doi.org/10.1007/s11011-015-9665-1.CrossRefPubMed

33.

Soliman RH, Farhan HM, Hegazy M, Oraby MI, Kamel SH, Hassan A. Impact of insulin resistance and metabolic syndrome on disability in patients with multiple sclerosis. Egypt J Neurol Psychiatry Neurosurg. 2020;56(1):18.CrossRef

34.

Dos Passos GR, Sato DK, Becker J, Fujihara K. Th17 cells pathways in multiple sclerosis and Neuromyelitis Optica Spectrum disorders: pathophysiological and therapeutic implications. Mediat Inflamm. 2016;2016:5314541.CrossRef

35.

Thoman ME, McKarns SC. Metabolomic Profiling in Neuromyelitis Optica Spectrum Disorder Biomarker Discovery. Metabolites. 2020;10(9):374. https://doi.org/10.3390/metabo10090374. PMID: 32961928; PMCID: PMC7570337.

36.

Lee YS, Wollam J, Olefsky JM. An integrated view of Immunometabolism. Cell. 2018;172(1–2):22–40. https://doi.org/10.1016/j.cell.2017.12.025.CrossRefPubMed

37.

Ozes ON, Akca H, Mayo LD, Gustin JA, Maehama T, Dixon JE, et al. A phosphatidylinositol 3-kinase/Akt/mTOR pathway mediates and PTEN antagonizes tumor necrosis factor inhibition of insulin signaling through insulin receptor substrate-1. Proc Natl Acad Sci U S A. 2001;98(8):4640–5. https://doi.org/10.1073/pnas.051042298.CrossRefPubMedPubMedCentral

38.

Tao L, Liu H, Gong Y. Role and mechanism of the Th17/Treg cell balance in the development and progression of insulin resistance. Mol Cell Biochem. 2019;459(1–2):183–8. https://doi.org/10.1007/s11010-019-03561-4.CrossRefPubMedPubMedCentral

39.

Kim JH, Bachmann RA, Chen J. Interleukin-6 and insulin resistance. Vitam Horm. 2009;80:613–33. https://doi.org/10.1016/S0083-6729(08)00621-3.CrossRefPubMed

40.

Uzawa A, Mori M, Kuwabara S. Cytokines and chemokines in neuromyelitis optica: pathogenetic and therapeutic implications. Brain Pathol (Zurich, Switzerland). 2014;24(1):67–73.CrossRef

41.

Araki M. Blockade of IL-6 signaling in neuromyelitis optica. Neurochem Int. 2019;130:104315. https://doi.org/10.1016/j.neuint.2018.10.012.CrossRefPubMed

42.

Fujihara K, Bennett JL, de Seze J, Haramura M, Kleiter I, Weinshenker BG, et al. Interleukin-6 in neuromyelitis optica spectrum disorder pathophysiology. Neurol Neuroimmunol Neuroinflamm. 2020;7(5):e841. https://doi.org/10.1212/NXI.0000000000000841.CrossRefPubMedPubMedCentral

43.

Monteiro C, Fernandes G, Kasahara TM, Barros PO, Dias AS, Araújo ACR, et al. The expansion of circulating IL-6 and IL-17-secreting follicular helper T cells is associated with neurological disabilities in neuromyelitis optica spectrum disorders. J Neuroimmunol. 2019;330:12–8. https://doi.org/10.1016/j.jneuroim.2019.01.015.CrossRefPubMed

44.

Cassese G, Arce S, Hauser AE, Lehnert K, Moewes B, Mostarac M, et al. Plasma cell survival is mediated by synergistic effects of cytokines and adhesion-dependent signals. J Immunol. 2003;171(4):1684–90. https://doi.org/10.4049/jimmunol.171.4.1684.CrossRefPubMed

45.

Araki M, Matsuoka T, Miyamoto K, Kusunoki S, Okamoto T, Murata M, et al. Efficacy of the anti–IL-6 receptor antibody tocilizumab in neuromyelitis optica: a pilot study. Neurology. 2014;82(15):1302–6. https://doi.org/10.1212/WNL.0000000000000317.CrossRefPubMedPubMedCentral

46.

İİçöz S, Tüzün E, Kürtüncü M, Durmuşş H, Mutlu M, Eraksoy M, et al. Enhanced IL-6 production in aquaporin-4 antibody positive neuromyelitis optica patients. Int J Neurosci. 2010;120(1):71–5. https://doi.org/10.3109/00207450903428970.CrossRef

47.

Correale J, Fiol M. Activation of humoral immunity and eosinophils in neuromyelitis optica. Neurology. 2004;63(12):2363–70. https://doi.org/10.1212/01.WNL.0000148481.80152.BF.CrossRefPubMed

48.

Heinrich PC, Behrmann I, Haan S, Hermanns HM, Müller-Newen G, Schaper F. Principles of interleukin (IL)-6-type cytokine signalling and its regulation. Biochem J. 2003;374(1):1–20. https://doi.org/10.1042/bj20030407.CrossRefPubMedPubMedCentral

49.

Chen L, Chen R, Wang H, Liang F. Mechanisms linking inflammation to insulin resistance. Int J Endocrinol. 2015;2015:508409.PubMedPubMedCentral

50.

Bermejo DA, Jackson SW, Gorosito-Serran M, Acosta-Rodriguez EV, Amezcua-Vesely MC, Sather BD, et al. Trypanosoma cruzi trans-sialidase initiates a program independent of the transcription factors RORγt and Ahr that leads to IL-17 production by activated B cells. Nat Immunol. 2013;14(5):514–22. https://doi.org/10.1038/ni.2569.CrossRefPubMedPubMedCentral

51.

Rauch PJ, Chudnovskiy A, Robbins CS, Weber GF, Etzrodt M, Hilgendorf I, et al. Innate response activator B cells protect against microbial sepsis. Science (New York, NY). 2012;335(6068):597–601.CrossRef

52.

Zúñiga LA, Shen W-J, Joyce-Shaikh B, Pyatnova EA, Richards AG, Thom C, et al. IL-17 regulates adipogenesis, glucose homeostasis, and obesity. J Immunol. 2010;185(11):6947–59. https://doi.org/10.4049/jimmunol.1001269.CrossRefPubMedPubMedCentral

53.

Lee SH, Jhun J, Byun JK, Kim EK, Jung K, Lee JE, et al. IL-17 axis accelerates the inflammatory progression of obese in mice via TBK1 and IKBKE pathway. Immunol Lett. 2017;184:67–75. https://doi.org/10.1016/j.imlet.2017.02.004.CrossRefPubMed

Title: The possible role of Interleukin-6 as a regulator of insulin sensitivity in patients with neuromyelitis optica spectrum disorder
Authors: Zhila Maghbooli
Abdorreza Naser Moghadasi
Nasim Rezaeimanesh
Abolfazl Omidifar
Tarlan Varzandi
Mohammad Ali Sahraian
Publication date: 01-12-2021
Publisher: BioMed Central
Keywords: Multiple Sclerosis
Insulins
Neuromyelitis Optica Spectrum Disease
Insulins
Published in: BMC Neurology / Issue 1/2021
Electronic ISSN: 1471-2377
DOI: https://doi.org/10.1186/s12883-021-02198-5

At a glance: The STEP trials

Springer Medicine

The possible role of Interleukin-6 as a regulator of insulin sensitivity in patients with neuromyelitis optica spectrum disorder

Abstract

Background

Methods

Results

Conclusions

At a glance: The STEP trials

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2021

Correction to: Gliosarcoma vs. glioblastoma: a retrospective case series using molecular profiling

Intravenous methadone causes acute toxic and delayed inflammatory encephalopathy with persistent neurocognitive impairments

Association of serum levels of antibodies against ALDOA and FH4 with transient ischemic attack and cerebral infarction

Using EEG and MEG to characterize extreme delta brush in a patient with anti-NMDA receptor encephalitis

Improving the understanding of how patients with non-dystrophic myotonia are selected for myotonia treatment with mexiletine (NaMuscla): outcomes of treatment impact using a European Delphi panel

Primary intracranial germ cell tumour originating from right brachium Pontis with hypertrophic Olivary degeneration: a case report